Medicare's Part D program paid significantly higher prices for drugs than either Medicaid or the Veterans Health Administration, a study by Carleton University and Public Citizen found.
After a decade of near-absence from the US market, the AstraZeneca drug Iressa (gefitinib) is back.
Emma Whitehead was a six-year-old girl battling relapsed leukemia for the third time when her parents were told she had run out of treatments. Her doctors offered one last hope—enrollment in a clinical trial at Children's Hospital of Philadelphia in a completely new immunotherapy. It was a phase I toxicity trial for both children and adult patients, and few patients on phase I trials are ever cured. But Emma's family was given the miracle they had prayed for. Five years later, Emma is now a happy, healthy, 11-year-old girl who likes to play piano and soccer. Emma is cured.
The Dan L. Duncan Cancer Center at Baylor College of Medicine and the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai received NCI designations this week.
Here is what Hagop Kantarjian has learned over the past two years of his campaign to lower the prices of cancer drugs:People would rather avoid disputing you head-on.
Many people are studying the rising prices of cancer drugs. A growing group of oncologists want to do something different: they want to give them a downward push.
NCI and FDA are recruiting three medical oncologists who would divide their time between clinical and regulatory duties—half at the FDA Office of Oncology and Hematology Products, and half at the NCI Center for Cancer Research.
MD Anderson Cancer Center has once again assumed its place at the top of the influential U.S. News & World Report rankings for 2015-2016.
Last week, the Centers for Medicare & Medicaid Services announced plans to support Medicare beneficiaries by reimbursing doctors for advance care planning beginning in January 2016.
FDA approved Iressa (gefitinib) for patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
